Best percentage change from baseline in target lesion size, and depth and duration of response. (A) Target lesion size, and (B) depth and duration of response of target lesions∗ in participants treated with favezelimab plus pembrolizumab in MK-4280-003, and best percentage change from baseline in (C) target lesion size, and (D) depth and duration of response of target lesions∗ in participants who received postprogression pembrolizumab in KEYNOTE-087. ∗Black dots represent each patient. Green lines show standard deviations from mean data along each axis. PD, progressive disease; SPD, sum of product of perpendicular diameters.